Table 4.

Trials using CAR-T cells technology targeting T-cell malignancies with their corresponding results.

NCT identificator	Target antigen	Co-stimulation	Treated population and sample size	Lympho-depletion	Response	CRS (%)	ICANS (%)	Comment	Ref
NCT03081910	CD5	CD28	T-ALL (n=4), T-NHL (n=5)	Flu/Cy	ORR: 44%, CR: 33%	56	11		(98)
NCT04689659	CD7	NR	T-ALL (n=20)	Flu/Cy	ORR and CR: 90%	100	15	Allogeneic cells; KDEL CD7 expression blocker	(67)
NCT04572308	CD7	4-1BB	T-ALL (n=14)	Flu/Cy	ORR and CR: 93%	100	7	EGFR co-expression allowing CAR T-cells elimination with cetuximab	(99)
NCT04916860	CD7	4-1BB	T-LBL (n=8)	Flu/Cy	ORR: 75%, CR: 63%	100	13	EGFR co-expression allowing CAR T-cells elimination with cetuximab	(100)
NCT04004637	CD7	NR	T-ALL/LBL (n=8)	Flu/Cy	CR: 88%	100	NR	CD7 PEBL	(101)
NCT04264078	CD7	NR	T-ALL (n=5)	NR	CR: 100%	100	0	allogeneic cells with CRISPR/Cas9 induced TCRα and CD7 disruption	(102)
NCT01316146	CD30	CD28	HL (n=7), ALCL (n=2)	None	HL: 29% CR, ALCL: 50% CR	0	0		(103)
NCT02690545NCT02917083	CD30	CD28	HL (n=41), EATL (n=1)	Ben, Ben/Flu, Flu/Cy	HL: ORR 72%, CR 59%	25	0		(104, 105)
NCT02259556	CD30	NR	HL (n=17), ALCL (n=1)	Flu/Cy	ORR: 39%, CR 0%	100	25	Repeated infusions	(106)
NCT02663297	CD30	CD28	HL (n=1), ALCL (n=1)	Ben/Flu	HL: 50% CR, ALCL: 0% ORR	NR	NR	Consolidation after ASCT	(107)

ALCL, anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; ASCT, autologous stem cell transplant; Ben, bendamustine; CR, complete remission; CRS, cytokine release syndrome; Cy, cyclophosphamide; EATL, enteropathy-associated T-cell lymphoma; EGFR, epidermal growth factor receptor; Flu, fludarabine; HL, Hodgkin’s lymphoma; ICANS, Immune effector cell-associated neurotoxicity syndrome; KDEL, K = lysine, D = aspartic acid, E = glutamic acid, L = leucin; NHL, non-Hodgkin’s lymphoma; NR, not reported; ORR, overall response rate; PEBL, protein expression blocker.